Global Platinum-based Antineoplastic Market Growth 2022-2028
The report requires updating with new data and is sent in 48 hours after order is placed.
A kind of chemotherapy medication
The global market for Platinum-based Antineoplastic is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
A kind of chemotherapy medication
Report Coverage
This latest report provides a deep insight into the global Platinum-based Antineoplastic market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Platinum-based Antineoplastic market, with both quantitative and qualitative data, to help readers understand how the Platinum-based Antineoplastic market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in Units.
Market Segmentation:
The study segments the Platinum-based Antineoplastic market and forecasts the market size by Type (Cisplatin, Carboplatin and Nedaplatin), by Application (Combination Therapy, Monotherapy and Targeted Therapy,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Chapter 1: Scope of Platinum-based Antineoplastic, Research Methodology, etc.
Chapter 2: Executive Summary, global Platinum-based Antineoplastic market size (sales and revenue) and CAGR, Platinum-based Antineoplastic market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Platinum-based Antineoplastic sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Platinum-based Antineoplastic sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Platinum-based Antineoplastic market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Pfizer, AstraZeneca, Roche, Sanofi, Bristol-Myers Squibb, Asta Medica GmbH, Simcere Pharmaceutical, Abbvie and Novartis, etc.
Chapter 14: Research Findings and Conclusion
A kind of chemotherapy medication
The global market for Platinum-based Antineoplastic is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
A kind of chemotherapy medication
Report Coverage
This latest report provides a deep insight into the global Platinum-based Antineoplastic market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Platinum-based Antineoplastic market, with both quantitative and qualitative data, to help readers understand how the Platinum-based Antineoplastic market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in Units.
Market Segmentation:
The study segments the Platinum-based Antineoplastic market and forecasts the market size by Type (Cisplatin, Carboplatin and Nedaplatin), by Application (Combination Therapy, Monotherapy and Targeted Therapy,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
- Cisplatin
- Carboplatin
- Nedaplatin
- Oxaliplatin
- Lobaplatin
- Cycloplatin
- Combination Therapy
- Monotherapy
- Targeted Therapy
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- AstraZeneca
- Roche
- Sanofi
- Bristol-Myers Squibb
- Asta Medica GmbH
- Simcere Pharmaceutical
- Abbvie
- Novartis
- GSK
- MSD
- Hengrui Medicine
- Hansoh Pharmaceutical Group
- ChiTaiTianQing Pharmaceutical Group
- CSPC Pharmaceutical Group
Chapter 1: Scope of Platinum-based Antineoplastic, Research Methodology, etc.
Chapter 2: Executive Summary, global Platinum-based Antineoplastic market size (sales and revenue) and CAGR, Platinum-based Antineoplastic market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Platinum-based Antineoplastic sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Platinum-based Antineoplastic sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Platinum-based Antineoplastic market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Pfizer, AstraZeneca, Roche, Sanofi, Bristol-Myers Squibb, Asta Medica GmbH, Simcere Pharmaceutical, Abbvie and Novartis, etc.
Chapter 14: Research Findings and Conclusion
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Platinum-based Antineoplastic Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Platinum-based Antineoplastic by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Platinum-based Antineoplastic by Country/Region, 2017, 2022 & 2028
2.2 Platinum-based Antineoplastic Segment by Type
2.2.1 Cisplatin
2.2.2 Carboplatin
2.2.3 Nedaplatin
2.2.4 Oxaliplatin
2.2.5 Lobaplatin
2.2.6 Cycloplatin
2.3 Platinum-based Antineoplastic Sales by Type
2.3.1 Global Platinum-based Antineoplastic Sales Market Share by Type (2017-2022)
2.3.2 Global Platinum-based Antineoplastic Revenue and Market Share by Type (2017-2022)
2.3.3 Global Platinum-based Antineoplastic Sale Price by Type (2017-2022)
2.4 Platinum-based Antineoplastic Segment by Application
2.4.1 Combination Therapy
2.4.2 Monotherapy
2.4.3 Targeted Therapy
2.5 Platinum-based Antineoplastic Sales by Application
2.5.1 Global Platinum-based Antineoplastic Sale Market Share by Application (2017-2022)
2.5.2 Global Platinum-based Antineoplastic Revenue and Market Share by Application (2017-2022)
2.5.3 Global Platinum-based Antineoplastic Sale Price by Application (2017-2022)
3 GLOBAL PLATINUM-BASED ANTINEOPLASTIC BY COMPANY
3.1 Global Platinum-based Antineoplastic Breakdown Data by Company
3.1.1 Global Platinum-based Antineoplastic Annual Sales by Company (2020-2022)
3.1.2 Global Platinum-based Antineoplastic Sales Market Share by Company (2020-2022)
3.2 Global Platinum-based Antineoplastic Annual Revenue by Company (2020-2022)
3.2.1 Global Platinum-based Antineoplastic Revenue by Company (2020-2022)
3.2.2 Global Platinum-based Antineoplastic Revenue Market Share by Company (2020-2022)
3.3 Global Platinum-based Antineoplastic Sale Price by Company
3.4 Key Manufacturers Platinum-based Antineoplastic Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Platinum-based Antineoplastic Product Location Distribution
3.4.2 Players Platinum-based Antineoplastic Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PLATINUM-BASED ANTINEOPLASTIC BY GEOGRAPHIC REGION
4.1 World Historic Platinum-based Antineoplastic Market Size by Geographic Region (2017-2022)
4.1.1 Global Platinum-based Antineoplastic Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Platinum-based Antineoplastic Annual Revenue by Geographic Region
4.2 World Historic Platinum-based Antineoplastic Market Size by Country/Region (2017-2022)
4.2.1 Global Platinum-based Antineoplastic Annual Sales by Country/Region (2017-2022)
4.2.2 Global Platinum-based Antineoplastic Annual Revenue by Country/Region
4.3 Americas Platinum-based Antineoplastic Sales Growth
4.4 APAC Platinum-based Antineoplastic Sales Growth
4.5 Europe Platinum-based Antineoplastic Sales Growth
4.6 Middle East & Africa Platinum-based Antineoplastic Sales Growth
5 AMERICAS
5.1 Americas Platinum-based Antineoplastic Sales by Country
5.1.1 Americas Platinum-based Antineoplastic Sales by Country (2017-2022)
5.1.2 Americas Platinum-based Antineoplastic Revenue by Country (2017-2022)
5.2 Americas Platinum-based Antineoplastic Sales by Type
5.3 Americas Platinum-based Antineoplastic Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Platinum-based Antineoplastic Sales by Region
6.1.1 APAC Platinum-based Antineoplastic Sales by Region (2017-2022)
6.1.2 APAC Platinum-based Antineoplastic Revenue by Region (2017-2022)
6.2 APAC Platinum-based Antineoplastic Sales by Type
6.3 APAC Platinum-based Antineoplastic Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Platinum-based Antineoplastic by Country
7.1.1 Europe Platinum-based Antineoplastic Sales by Country (2017-2022)
7.1.2 Europe Platinum-based Antineoplastic Revenue by Country (2017-2022)
7.2 Europe Platinum-based Antineoplastic Sales by Type
7.3 Europe Platinum-based Antineoplastic Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Platinum-based Antineoplastic by Country
8.1.1 Middle East & Africa Platinum-based Antineoplastic Sales by Country (2017-2022)
8.1.2 Middle East & Africa Platinum-based Antineoplastic Revenue by Country (2017-2022)
8.2 Middle East & Africa Platinum-based Antineoplastic Sales by Type
8.3 Middle East & Africa Platinum-based Antineoplastic Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Platinum-based Antineoplastic
10.3 Manufacturing Process Analysis of Platinum-based Antineoplastic
10.4 Industry Chain Structure of Platinum-based Antineoplastic
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Platinum-based Antineoplastic Distributors
11.3 Platinum-based Antineoplastic Customer
12 WORLD FORECAST REVIEW FOR PLATINUM-BASED ANTINEOPLASTIC BY GEOGRAPHIC REGION
12.1 Global Platinum-based Antineoplastic Market Size Forecast by Region
12.1.1 Global Platinum-based Antineoplastic Forecast by Region (2023-2028)
12.1.2 Global Platinum-based Antineoplastic Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Platinum-based Antineoplastic Forecast by Type
12.7 Global Platinum-based Antineoplastic Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Platinum-based Antineoplastic Product Offered
13.1.3 Pfizer Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Platinum-based Antineoplastic Product Offered
13.2.3 AstraZeneca Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Platinum-based Antineoplastic Product Offered
13.3.3 Roche Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Platinum-based Antineoplastic Product Offered
13.4.3 Sanofi Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Bristol-Myers Squibb
13.5.1 Bristol-Myers Squibb Company Information
13.5.2 Bristol-Myers Squibb Platinum-based Antineoplastic Product Offered
13.5.3 Bristol-Myers Squibb Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Bristol-Myers Squibb Main Business Overview
13.5.5 Bristol-Myers Squibb Latest Developments
13.6 Asta Medica GmbH
13.6.1 Asta Medica GmbH Company Information
13.6.2 Asta Medica GmbH Platinum-based Antineoplastic Product Offered
13.6.3 Asta Medica GmbH Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Asta Medica GmbH Main Business Overview
13.6.5 Asta Medica GmbH Latest Developments
13.7 Simcere Pharmaceutical
13.7.1 Simcere Pharmaceutical Company Information
13.7.2 Simcere Pharmaceutical Platinum-based Antineoplastic Product Offered
13.7.3 Simcere Pharmaceutical Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Simcere Pharmaceutical Main Business Overview
13.7.5 Simcere Pharmaceutical Latest Developments
13.8 Abbvie
13.8.1 Abbvie Company Information
13.8.2 Abbvie Platinum-based Antineoplastic Product Offered
13.8.3 Abbvie Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Abbvie Main Business Overview
13.8.5 Abbvie Latest Developments
13.9 Novartis
13.9.1 Novartis Company Information
13.9.2 Novartis Platinum-based Antineoplastic Product Offered
13.9.3 Novartis Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Novartis Main Business Overview
13.9.5 Novartis Latest Developments
13.10 GSK
13.10.1 GSK Company Information
13.10.2 GSK Platinum-based Antineoplastic Product Offered
13.10.3 GSK Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 GSK Main Business Overview
13.10.5 GSK Latest Developments
13.11 MSD
13.11.1 MSD Company Information
13.11.2 MSD Platinum-based Antineoplastic Product Offered
13.11.3 MSD Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 MSD Main Business Overview
13.11.5 MSD Latest Developments
13.12 Hengrui Medicine
13.12.1 Hengrui Medicine Company Information
13.12.2 Hengrui Medicine Platinum-based Antineoplastic Product Offered
13.12.3 Hengrui Medicine Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Hengrui Medicine Main Business Overview
13.12.5 Hengrui Medicine Latest Developments
13.13 Hansoh Pharmaceutical Group
13.13.1 Hansoh Pharmaceutical Group Company Information
13.13.2 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Offered
13.13.3 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Hansoh Pharmaceutical Group Main Business Overview
13.13.5 Hansoh Pharmaceutical Group Latest Developments
13.14 ChiTaiTianQing Pharmaceutical Group
13.14.1 ChiTaiTianQing Pharmaceutical Group Company Information
13.14.2 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Offered
13.14.3 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 ChiTaiTianQing Pharmaceutical Group Main Business Overview
13.14.5 ChiTaiTianQing Pharmaceutical Group Latest Developments
13.15 CSPC Pharmaceutical Group
13.15.1 CSPC Pharmaceutical Group Company Information
13.15.2 CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Offered
13.15.3 CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 CSPC Pharmaceutical Group Main Business Overview
13.15.5 CSPC Pharmaceutical Group Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Platinum-based Antineoplastic Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Platinum-based Antineoplastic by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Platinum-based Antineoplastic by Country/Region, 2017, 2022 & 2028
2.2 Platinum-based Antineoplastic Segment by Type
2.2.1 Cisplatin
2.2.2 Carboplatin
2.2.3 Nedaplatin
2.2.4 Oxaliplatin
2.2.5 Lobaplatin
2.2.6 Cycloplatin
2.3 Platinum-based Antineoplastic Sales by Type
2.3.1 Global Platinum-based Antineoplastic Sales Market Share by Type (2017-2022)
2.3.2 Global Platinum-based Antineoplastic Revenue and Market Share by Type (2017-2022)
2.3.3 Global Platinum-based Antineoplastic Sale Price by Type (2017-2022)
2.4 Platinum-based Antineoplastic Segment by Application
2.4.1 Combination Therapy
2.4.2 Monotherapy
2.4.3 Targeted Therapy
2.5 Platinum-based Antineoplastic Sales by Application
2.5.1 Global Platinum-based Antineoplastic Sale Market Share by Application (2017-2022)
2.5.2 Global Platinum-based Antineoplastic Revenue and Market Share by Application (2017-2022)
2.5.3 Global Platinum-based Antineoplastic Sale Price by Application (2017-2022)
3 GLOBAL PLATINUM-BASED ANTINEOPLASTIC BY COMPANY
3.1 Global Platinum-based Antineoplastic Breakdown Data by Company
3.1.1 Global Platinum-based Antineoplastic Annual Sales by Company (2020-2022)
3.1.2 Global Platinum-based Antineoplastic Sales Market Share by Company (2020-2022)
3.2 Global Platinum-based Antineoplastic Annual Revenue by Company (2020-2022)
3.2.1 Global Platinum-based Antineoplastic Revenue by Company (2020-2022)
3.2.2 Global Platinum-based Antineoplastic Revenue Market Share by Company (2020-2022)
3.3 Global Platinum-based Antineoplastic Sale Price by Company
3.4 Key Manufacturers Platinum-based Antineoplastic Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Platinum-based Antineoplastic Product Location Distribution
3.4.2 Players Platinum-based Antineoplastic Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PLATINUM-BASED ANTINEOPLASTIC BY GEOGRAPHIC REGION
4.1 World Historic Platinum-based Antineoplastic Market Size by Geographic Region (2017-2022)
4.1.1 Global Platinum-based Antineoplastic Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Platinum-based Antineoplastic Annual Revenue by Geographic Region
4.2 World Historic Platinum-based Antineoplastic Market Size by Country/Region (2017-2022)
4.2.1 Global Platinum-based Antineoplastic Annual Sales by Country/Region (2017-2022)
4.2.2 Global Platinum-based Antineoplastic Annual Revenue by Country/Region
4.3 Americas Platinum-based Antineoplastic Sales Growth
4.4 APAC Platinum-based Antineoplastic Sales Growth
4.5 Europe Platinum-based Antineoplastic Sales Growth
4.6 Middle East & Africa Platinum-based Antineoplastic Sales Growth
5 AMERICAS
5.1 Americas Platinum-based Antineoplastic Sales by Country
5.1.1 Americas Platinum-based Antineoplastic Sales by Country (2017-2022)
5.1.2 Americas Platinum-based Antineoplastic Revenue by Country (2017-2022)
5.2 Americas Platinum-based Antineoplastic Sales by Type
5.3 Americas Platinum-based Antineoplastic Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Platinum-based Antineoplastic Sales by Region
6.1.1 APAC Platinum-based Antineoplastic Sales by Region (2017-2022)
6.1.2 APAC Platinum-based Antineoplastic Revenue by Region (2017-2022)
6.2 APAC Platinum-based Antineoplastic Sales by Type
6.3 APAC Platinum-based Antineoplastic Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Platinum-based Antineoplastic by Country
7.1.1 Europe Platinum-based Antineoplastic Sales by Country (2017-2022)
7.1.2 Europe Platinum-based Antineoplastic Revenue by Country (2017-2022)
7.2 Europe Platinum-based Antineoplastic Sales by Type
7.3 Europe Platinum-based Antineoplastic Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Platinum-based Antineoplastic by Country
8.1.1 Middle East & Africa Platinum-based Antineoplastic Sales by Country (2017-2022)
8.1.2 Middle East & Africa Platinum-based Antineoplastic Revenue by Country (2017-2022)
8.2 Middle East & Africa Platinum-based Antineoplastic Sales by Type
8.3 Middle East & Africa Platinum-based Antineoplastic Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Platinum-based Antineoplastic
10.3 Manufacturing Process Analysis of Platinum-based Antineoplastic
10.4 Industry Chain Structure of Platinum-based Antineoplastic
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Platinum-based Antineoplastic Distributors
11.3 Platinum-based Antineoplastic Customer
12 WORLD FORECAST REVIEW FOR PLATINUM-BASED ANTINEOPLASTIC BY GEOGRAPHIC REGION
12.1 Global Platinum-based Antineoplastic Market Size Forecast by Region
12.1.1 Global Platinum-based Antineoplastic Forecast by Region (2023-2028)
12.1.2 Global Platinum-based Antineoplastic Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Platinum-based Antineoplastic Forecast by Type
12.7 Global Platinum-based Antineoplastic Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Platinum-based Antineoplastic Product Offered
13.1.3 Pfizer Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca Platinum-based Antineoplastic Product Offered
13.2.3 AstraZeneca Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Roche
13.3.1 Roche Company Information
13.3.2 Roche Platinum-based Antineoplastic Product Offered
13.3.3 Roche Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Roche Main Business Overview
13.3.5 Roche Latest Developments
13.4 Sanofi
13.4.1 Sanofi Company Information
13.4.2 Sanofi Platinum-based Antineoplastic Product Offered
13.4.3 Sanofi Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Sanofi Main Business Overview
13.4.5 Sanofi Latest Developments
13.5 Bristol-Myers Squibb
13.5.1 Bristol-Myers Squibb Company Information
13.5.2 Bristol-Myers Squibb Platinum-based Antineoplastic Product Offered
13.5.3 Bristol-Myers Squibb Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Bristol-Myers Squibb Main Business Overview
13.5.5 Bristol-Myers Squibb Latest Developments
13.6 Asta Medica GmbH
13.6.1 Asta Medica GmbH Company Information
13.6.2 Asta Medica GmbH Platinum-based Antineoplastic Product Offered
13.6.3 Asta Medica GmbH Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Asta Medica GmbH Main Business Overview
13.6.5 Asta Medica GmbH Latest Developments
13.7 Simcere Pharmaceutical
13.7.1 Simcere Pharmaceutical Company Information
13.7.2 Simcere Pharmaceutical Platinum-based Antineoplastic Product Offered
13.7.3 Simcere Pharmaceutical Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Simcere Pharmaceutical Main Business Overview
13.7.5 Simcere Pharmaceutical Latest Developments
13.8 Abbvie
13.8.1 Abbvie Company Information
13.8.2 Abbvie Platinum-based Antineoplastic Product Offered
13.8.3 Abbvie Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Abbvie Main Business Overview
13.8.5 Abbvie Latest Developments
13.9 Novartis
13.9.1 Novartis Company Information
13.9.2 Novartis Platinum-based Antineoplastic Product Offered
13.9.3 Novartis Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Novartis Main Business Overview
13.9.5 Novartis Latest Developments
13.10 GSK
13.10.1 GSK Company Information
13.10.2 GSK Platinum-based Antineoplastic Product Offered
13.10.3 GSK Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 GSK Main Business Overview
13.10.5 GSK Latest Developments
13.11 MSD
13.11.1 MSD Company Information
13.11.2 MSD Platinum-based Antineoplastic Product Offered
13.11.3 MSD Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 MSD Main Business Overview
13.11.5 MSD Latest Developments
13.12 Hengrui Medicine
13.12.1 Hengrui Medicine Company Information
13.12.2 Hengrui Medicine Platinum-based Antineoplastic Product Offered
13.12.3 Hengrui Medicine Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Hengrui Medicine Main Business Overview
13.12.5 Hengrui Medicine Latest Developments
13.13 Hansoh Pharmaceutical Group
13.13.1 Hansoh Pharmaceutical Group Company Information
13.13.2 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Offered
13.13.3 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Hansoh Pharmaceutical Group Main Business Overview
13.13.5 Hansoh Pharmaceutical Group Latest Developments
13.14 ChiTaiTianQing Pharmaceutical Group
13.14.1 ChiTaiTianQing Pharmaceutical Group Company Information
13.14.2 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Offered
13.14.3 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 ChiTaiTianQing Pharmaceutical Group Main Business Overview
13.14.5 ChiTaiTianQing Pharmaceutical Group Latest Developments
13.15 CSPC Pharmaceutical Group
13.15.1 CSPC Pharmaceutical Group Company Information
13.15.2 CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Offered
13.15.3 CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 CSPC Pharmaceutical Group Main Business Overview
13.15.5 CSPC Pharmaceutical Group Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Platinum-based Antineoplastic Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Platinum-based Antineoplastic Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Cisplatin
Table 4. Major Players of Carboplatin
Table 5. Major Players of Nedaplatin
Table 6. Major Players of Oxaliplatin
Table 7. Major Players of Lobaplatin
Table 8. Major Players of Cycloplatin
Table 9. Global Platinum-based Antineoplastic Sales by Type (2017-2022) & (Units)
Table 10. Global Platinum-based Antineoplastic Sales Market Share by Type (2017-2022)
Table 11. Global Platinum-based Antineoplastic Revenue by Type (2017-2022) & ($ million)
Table 12. Global Platinum-based Antineoplastic Revenue Market Share by Type (2017-2022)
Table 13. Global Platinum-based Antineoplastic Sale Price by Type (2017-2022) & (US$/Unit)
Table 14. Global Platinum-based Antineoplastic Sales by Application (2017-2022) & (Units)
Table 15. Global Platinum-based Antineoplastic Sales Market Share by Application (2017-2022)
Table 16. Global Platinum-based Antineoplastic Revenue by Application (2017-2022)
Table 17. Global Platinum-based Antineoplastic Revenue Market Share by Application (2017-2022)
Table 18. Global Platinum-based Antineoplastic Sale Price by Application (2017-2022) & (US$/Unit)
Table 19. Global Platinum-based Antineoplastic Sales by Company (2020-2022) & (Units)
Table 20. Global Platinum-based Antineoplastic Sales Market Share by Company (2020-2022)
Table 21. Global Platinum-based Antineoplastic Revenue by Company (2020-2022) ($ Millions)
Table 22. Global Platinum-based Antineoplastic Revenue Market Share by Company (2020-2022)
Table 23. Global Platinum-based Antineoplastic Sale Price by Company (2020-2022) & (US$/Unit)
Table 24. Key Manufacturers Platinum-based Antineoplastic Producing Area Distribution and Sales Area
Table 25. Players Platinum-based Antineoplastic Products Offered
Table 26. Platinum-based Antineoplastic Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Platinum-based Antineoplastic Sales by Geographic Region (2017-2022) & (Units)
Table 30. Global Platinum-based Antineoplastic Sales Market Share Geographic Region (2017-2022)
Table 31. Global Platinum-based Antineoplastic Revenue by Geographic Region (2017-2022) & ($ millions)
Table 32. Global Platinum-based Antineoplastic Revenue Market Share by Geographic Region (2017-2022)
Table 33. Global Platinum-based Antineoplastic Sales by Country/Region (2017-2022) & (Units)
Table 34. Global Platinum-based Antineoplastic Sales Market Share by Country/Region (2017-2022)
Table 35. Global Platinum-based Antineoplastic Revenue by Country/Region (2017-2022) & ($ millions)
Table 36. Global Platinum-based Antineoplastic Revenue Market Share by Country/Region (2017-2022)
Table 37. Americas Platinum-based Antineoplastic Sales by Country (2017-2022) & (Units)
Table 38. Americas Platinum-based Antineoplastic Sales Market Share by Country (2017-2022)
Table 39. Americas Platinum-based Antineoplastic Revenue by Country (2017-2022) & ($ Millions)
Table 40. Americas Platinum-based Antineoplastic Revenue Market Share by Country (2017-2022)
Table 41. Americas Platinum-based Antineoplastic Sales by Type (2017-2022) & (Units)
Table 42. Americas Platinum-based Antineoplastic Sales Market Share by Type (2017-2022)
Table 43. Americas Platinum-based Antineoplastic Sales by Application (2017-2022) & (Units)
Table 44. Americas Platinum-based Antineoplastic Sales Market Share by Application (2017-2022)
Table 45. APAC Platinum-based Antineoplastic Sales by Region (2017-2022) & (Units)
Table 46. APAC Platinum-based Antineoplastic Sales Market Share by Region (2017-2022)
Table 47. APAC Platinum-based Antineoplastic Revenue by Region (2017-2022) & ($ Millions)
Table 48. APAC Platinum-based Antineoplastic Revenue Market Share by Region (2017-2022)
Table 49. APAC Platinum-based Antineoplastic Sales by Type (2017-2022) & (Units)
Table 50. APAC Platinum-based Antineoplastic Sales Market Share by Type (2017-2022)
Table 51. APAC Platinum-based Antineoplastic Sales by Application (2017-2022) & (Units)
Table 52. APAC Platinum-based Antineoplastic Sales Market Share by Application (2017-2022)
Table 53. Europe Platinum-based Antineoplastic Sales by Country (2017-2022) & (Units)
Table 54. Europe Platinum-based Antineoplastic Sales Market Share by Country (2017-2022)
Table 55. Europe Platinum-based Antineoplastic Revenue by Country (2017-2022) & ($ Millions)
Table 56. Europe Platinum-based Antineoplastic Revenue Market Share by Country (2017-2022)
Table 57. Europe Platinum-based Antineoplastic Sales by Type (2017-2022) & (Units)
Table 58. Europe Platinum-based Antineoplastic Sales Market Share by Type (2017-2022)
Table 59. Europe Platinum-based Antineoplastic Sales by Application (2017-2022) & (Units)
Table 60. Europe Platinum-based Antineoplastic Sales Market Share by Application (2017-2022)
Table 61. Middle East & Africa Platinum-based Antineoplastic Sales by Country (2017-2022) & (Units)
Table 62. Middle East & Africa Platinum-based Antineoplastic Sales Market Share by Country (2017-2022)
Table 63. Middle East & Africa Platinum-based Antineoplastic Revenue by Country (2017-2022) & ($ Millions)
Table 64. Middle East & Africa Platinum-based Antineoplastic Revenue Market Share by Country (2017-2022)
Table 65. Middle East & Africa Platinum-based Antineoplastic Sales by Type (2017-2022) & (Units)
Table 66. Middle East & Africa Platinum-based Antineoplastic Sales Market Share by Type (2017-2022)
Table 67. Middle East & Africa Platinum-based Antineoplastic Sales by Application (2017-2022) & (Units)
Table 68. Middle East & Africa Platinum-based Antineoplastic Sales Market Share by Application (2017-2022)
Table 69. Key Market Drivers & Growth Opportunities of Platinum-based Antineoplastic
Table 70. Key Market Challenges & Risks of Platinum-based Antineoplastic
Table 71. Key Industry Trends of Platinum-based Antineoplastic
Table 72. Platinum-based Antineoplastic Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. Platinum-based Antineoplastic Distributors List
Table 75. Platinum-based Antineoplastic Customer List
Table 76. Global Platinum-based Antineoplastic Sales Forecast by Region (2023-2028) & (Units)
Table 77. Global Platinum-based Antineoplastic Sales Market Forecast by Region
Table 78. Global Platinum-based Antineoplastic Revenue Forecast by Region (2023-2028) & ($ millions)
Table 79. Global Platinum-based Antineoplastic Revenue Market Share Forecast by Region (2023-2028)
Table 80. Americas Platinum-based Antineoplastic Sales Forecast by Country (2023-2028) & (Units)
Table 81. Americas Platinum-based Antineoplastic Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. APAC Platinum-based Antineoplastic Sales Forecast by Region (2023-2028) & (Units)
Table 83. APAC Platinum-based Antineoplastic Revenue Forecast by Region (2023-2028) & ($ millions)
Table 84. Europe Platinum-based Antineoplastic Sales Forecast by Country (2023-2028) & (Units)
Table 85. Europe Platinum-based Antineoplastic Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Middle East & Africa Platinum-based Antineoplastic Sales Forecast by Country (2023-2028) & (Units)
Table 87. Middle East & Africa Platinum-based Antineoplastic Revenue Forecast by Country (2023-2028) & ($ millions)
Table 88. Global Platinum-based Antineoplastic Sales Forecast by Type (2023-2028) & (Units)
Table 89. Global Platinum-based Antineoplastic Sales Market Share Forecast by Type (2023-2028)
Table 90. Global Platinum-based Antineoplastic Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 91. Global Platinum-based Antineoplastic Revenue Market Share Forecast by Type (2023-2028)
Table 92. Global Platinum-based Antineoplastic Sales Forecast by Application (2023-2028) & (Units)
Table 93. Global Platinum-based Antineoplastic Sales Market Share Forecast by Application (2023-2028)
Table 94. Global Platinum-based Antineoplastic Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 95. Global Platinum-based Antineoplastic Revenue Market Share Forecast by Application (2023-2028)
Table 96. Pfizer Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 97. Pfizer Platinum-based Antineoplastic Product Offered
Table 98. Pfizer Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 99. Pfizer Main Business
Table 100. Pfizer Latest Developments
Table 101. AstraZeneca Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 102. AstraZeneca Platinum-based Antineoplastic Product Offered
Table 103. AstraZeneca Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 104. AstraZeneca Main Business
Table 105. AstraZeneca Latest Developments
Table 106. Roche Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 107. Roche Platinum-based Antineoplastic Product Offered
Table 108. Roche Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 109. Roche Main Business
Table 110. Roche Latest Developments
Table 111. Sanofi Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 112. Sanofi Platinum-based Antineoplastic Product Offered
Table 113. Sanofi Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 114. Sanofi Main Business
Table 115. Sanofi Latest Developments
Table 116. Bristol-Myers Squibb Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 117. Bristol-Myers Squibb Platinum-based Antineoplastic Product Offered
Table 118. Bristol-Myers Squibb Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 119. Bristol-Myers Squibb Main Business
Table 120. Bristol-Myers Squibb Latest Developments
Table 121. Asta Medica GmbH Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 122. Asta Medica GmbH Platinum-based Antineoplastic Product Offered
Table 123. Asta Medica GmbH Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 124. Asta Medica GmbH Main Business
Table 125. Asta Medica GmbH Latest Developments
Table 126. Simcere Pharmaceutical Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 127. Simcere Pharmaceutical Platinum-based Antineoplastic Product Offered
Table 128. Simcere Pharmaceutical Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 129. Simcere Pharmaceutical Main Business
Table 130. Simcere Pharmaceutical Latest Developments
Table 131. Abbvie Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 132. Abbvie Platinum-based Antineoplastic Product Offered
Table 133. Abbvie Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 134. Abbvie Main Business
Table 135. Abbvie Latest Developments
Table 136. Novartis Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 137. Novartis Platinum-based Antineoplastic Product Offered
Table 138. Novartis Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 139. Novartis Main Business
Table 140. Novartis Latest Developments
Table 141. GSK Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 142. GSK Platinum-based Antineoplastic Product Offered
Table 143. GSK Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 144. GSK Main Business
Table 145. GSK Latest Developments
Table 146. MSD Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 147. MSD Platinum-based Antineoplastic Product Offered
Table 148. MSD Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 149. MSD Main Business
Table 150. MSD Latest Developments
Table 151. Hengrui Medicine Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 152. Hengrui Medicine Platinum-based Antineoplastic Product Offered
Table 153. Hengrui Medicine Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 154. Hengrui Medicine Main Business
Table 155. Hengrui Medicine Latest Developments
Table 156. Hansoh Pharmaceutical Group Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 157. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Offered
Table 158. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 159. Hansoh Pharmaceutical Group Main Business
Table 160. Hansoh Pharmaceutical Group Latest Developments
Table 161. ChiTaiTianQing Pharmaceutical Group Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 162. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Offered
Table 163. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 164. ChiTaiTianQing Pharmaceutical Group Main Business
Table 165. ChiTaiTianQing Pharmaceutical Group Latest Developments
Table 166. CSPC Pharmaceutical Group Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 167. CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Offered
Table 168. CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 169. CSPC Pharmaceutical Group Main Business
Table 170. CSPC Pharmaceutical Group Latest Developments
Table 1. Platinum-based Antineoplastic Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Platinum-based Antineoplastic Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Cisplatin
Table 4. Major Players of Carboplatin
Table 5. Major Players of Nedaplatin
Table 6. Major Players of Oxaliplatin
Table 7. Major Players of Lobaplatin
Table 8. Major Players of Cycloplatin
Table 9. Global Platinum-based Antineoplastic Sales by Type (2017-2022) & (Units)
Table 10. Global Platinum-based Antineoplastic Sales Market Share by Type (2017-2022)
Table 11. Global Platinum-based Antineoplastic Revenue by Type (2017-2022) & ($ million)
Table 12. Global Platinum-based Antineoplastic Revenue Market Share by Type (2017-2022)
Table 13. Global Platinum-based Antineoplastic Sale Price by Type (2017-2022) & (US$/Unit)
Table 14. Global Platinum-based Antineoplastic Sales by Application (2017-2022) & (Units)
Table 15. Global Platinum-based Antineoplastic Sales Market Share by Application (2017-2022)
Table 16. Global Platinum-based Antineoplastic Revenue by Application (2017-2022)
Table 17. Global Platinum-based Antineoplastic Revenue Market Share by Application (2017-2022)
Table 18. Global Platinum-based Antineoplastic Sale Price by Application (2017-2022) & (US$/Unit)
Table 19. Global Platinum-based Antineoplastic Sales by Company (2020-2022) & (Units)
Table 20. Global Platinum-based Antineoplastic Sales Market Share by Company (2020-2022)
Table 21. Global Platinum-based Antineoplastic Revenue by Company (2020-2022) ($ Millions)
Table 22. Global Platinum-based Antineoplastic Revenue Market Share by Company (2020-2022)
Table 23. Global Platinum-based Antineoplastic Sale Price by Company (2020-2022) & (US$/Unit)
Table 24. Key Manufacturers Platinum-based Antineoplastic Producing Area Distribution and Sales Area
Table 25. Players Platinum-based Antineoplastic Products Offered
Table 26. Platinum-based Antineoplastic Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Platinum-based Antineoplastic Sales by Geographic Region (2017-2022) & (Units)
Table 30. Global Platinum-based Antineoplastic Sales Market Share Geographic Region (2017-2022)
Table 31. Global Platinum-based Antineoplastic Revenue by Geographic Region (2017-2022) & ($ millions)
Table 32. Global Platinum-based Antineoplastic Revenue Market Share by Geographic Region (2017-2022)
Table 33. Global Platinum-based Antineoplastic Sales by Country/Region (2017-2022) & (Units)
Table 34. Global Platinum-based Antineoplastic Sales Market Share by Country/Region (2017-2022)
Table 35. Global Platinum-based Antineoplastic Revenue by Country/Region (2017-2022) & ($ millions)
Table 36. Global Platinum-based Antineoplastic Revenue Market Share by Country/Region (2017-2022)
Table 37. Americas Platinum-based Antineoplastic Sales by Country (2017-2022) & (Units)
Table 38. Americas Platinum-based Antineoplastic Sales Market Share by Country (2017-2022)
Table 39. Americas Platinum-based Antineoplastic Revenue by Country (2017-2022) & ($ Millions)
Table 40. Americas Platinum-based Antineoplastic Revenue Market Share by Country (2017-2022)
Table 41. Americas Platinum-based Antineoplastic Sales by Type (2017-2022) & (Units)
Table 42. Americas Platinum-based Antineoplastic Sales Market Share by Type (2017-2022)
Table 43. Americas Platinum-based Antineoplastic Sales by Application (2017-2022) & (Units)
Table 44. Americas Platinum-based Antineoplastic Sales Market Share by Application (2017-2022)
Table 45. APAC Platinum-based Antineoplastic Sales by Region (2017-2022) & (Units)
Table 46. APAC Platinum-based Antineoplastic Sales Market Share by Region (2017-2022)
Table 47. APAC Platinum-based Antineoplastic Revenue by Region (2017-2022) & ($ Millions)
Table 48. APAC Platinum-based Antineoplastic Revenue Market Share by Region (2017-2022)
Table 49. APAC Platinum-based Antineoplastic Sales by Type (2017-2022) & (Units)
Table 50. APAC Platinum-based Antineoplastic Sales Market Share by Type (2017-2022)
Table 51. APAC Platinum-based Antineoplastic Sales by Application (2017-2022) & (Units)
Table 52. APAC Platinum-based Antineoplastic Sales Market Share by Application (2017-2022)
Table 53. Europe Platinum-based Antineoplastic Sales by Country (2017-2022) & (Units)
Table 54. Europe Platinum-based Antineoplastic Sales Market Share by Country (2017-2022)
Table 55. Europe Platinum-based Antineoplastic Revenue by Country (2017-2022) & ($ Millions)
Table 56. Europe Platinum-based Antineoplastic Revenue Market Share by Country (2017-2022)
Table 57. Europe Platinum-based Antineoplastic Sales by Type (2017-2022) & (Units)
Table 58. Europe Platinum-based Antineoplastic Sales Market Share by Type (2017-2022)
Table 59. Europe Platinum-based Antineoplastic Sales by Application (2017-2022) & (Units)
Table 60. Europe Platinum-based Antineoplastic Sales Market Share by Application (2017-2022)
Table 61. Middle East & Africa Platinum-based Antineoplastic Sales by Country (2017-2022) & (Units)
Table 62. Middle East & Africa Platinum-based Antineoplastic Sales Market Share by Country (2017-2022)
Table 63. Middle East & Africa Platinum-based Antineoplastic Revenue by Country (2017-2022) & ($ Millions)
Table 64. Middle East & Africa Platinum-based Antineoplastic Revenue Market Share by Country (2017-2022)
Table 65. Middle East & Africa Platinum-based Antineoplastic Sales by Type (2017-2022) & (Units)
Table 66. Middle East & Africa Platinum-based Antineoplastic Sales Market Share by Type (2017-2022)
Table 67. Middle East & Africa Platinum-based Antineoplastic Sales by Application (2017-2022) & (Units)
Table 68. Middle East & Africa Platinum-based Antineoplastic Sales Market Share by Application (2017-2022)
Table 69. Key Market Drivers & Growth Opportunities of Platinum-based Antineoplastic
Table 70. Key Market Challenges & Risks of Platinum-based Antineoplastic
Table 71. Key Industry Trends of Platinum-based Antineoplastic
Table 72. Platinum-based Antineoplastic Raw Material
Table 73. Key Suppliers of Raw Materials
Table 74. Platinum-based Antineoplastic Distributors List
Table 75. Platinum-based Antineoplastic Customer List
Table 76. Global Platinum-based Antineoplastic Sales Forecast by Region (2023-2028) & (Units)
Table 77. Global Platinum-based Antineoplastic Sales Market Forecast by Region
Table 78. Global Platinum-based Antineoplastic Revenue Forecast by Region (2023-2028) & ($ millions)
Table 79. Global Platinum-based Antineoplastic Revenue Market Share Forecast by Region (2023-2028)
Table 80. Americas Platinum-based Antineoplastic Sales Forecast by Country (2023-2028) & (Units)
Table 81. Americas Platinum-based Antineoplastic Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. APAC Platinum-based Antineoplastic Sales Forecast by Region (2023-2028) & (Units)
Table 83. APAC Platinum-based Antineoplastic Revenue Forecast by Region (2023-2028) & ($ millions)
Table 84. Europe Platinum-based Antineoplastic Sales Forecast by Country (2023-2028) & (Units)
Table 85. Europe Platinum-based Antineoplastic Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Middle East & Africa Platinum-based Antineoplastic Sales Forecast by Country (2023-2028) & (Units)
Table 87. Middle East & Africa Platinum-based Antineoplastic Revenue Forecast by Country (2023-2028) & ($ millions)
Table 88. Global Platinum-based Antineoplastic Sales Forecast by Type (2023-2028) & (Units)
Table 89. Global Platinum-based Antineoplastic Sales Market Share Forecast by Type (2023-2028)
Table 90. Global Platinum-based Antineoplastic Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 91. Global Platinum-based Antineoplastic Revenue Market Share Forecast by Type (2023-2028)
Table 92. Global Platinum-based Antineoplastic Sales Forecast by Application (2023-2028) & (Units)
Table 93. Global Platinum-based Antineoplastic Sales Market Share Forecast by Application (2023-2028)
Table 94. Global Platinum-based Antineoplastic Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 95. Global Platinum-based Antineoplastic Revenue Market Share Forecast by Application (2023-2028)
Table 96. Pfizer Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 97. Pfizer Platinum-based Antineoplastic Product Offered
Table 98. Pfizer Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 99. Pfizer Main Business
Table 100. Pfizer Latest Developments
Table 101. AstraZeneca Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 102. AstraZeneca Platinum-based Antineoplastic Product Offered
Table 103. AstraZeneca Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 104. AstraZeneca Main Business
Table 105. AstraZeneca Latest Developments
Table 106. Roche Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 107. Roche Platinum-based Antineoplastic Product Offered
Table 108. Roche Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 109. Roche Main Business
Table 110. Roche Latest Developments
Table 111. Sanofi Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 112. Sanofi Platinum-based Antineoplastic Product Offered
Table 113. Sanofi Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 114. Sanofi Main Business
Table 115. Sanofi Latest Developments
Table 116. Bristol-Myers Squibb Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 117. Bristol-Myers Squibb Platinum-based Antineoplastic Product Offered
Table 118. Bristol-Myers Squibb Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 119. Bristol-Myers Squibb Main Business
Table 120. Bristol-Myers Squibb Latest Developments
Table 121. Asta Medica GmbH Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 122. Asta Medica GmbH Platinum-based Antineoplastic Product Offered
Table 123. Asta Medica GmbH Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 124. Asta Medica GmbH Main Business
Table 125. Asta Medica GmbH Latest Developments
Table 126. Simcere Pharmaceutical Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 127. Simcere Pharmaceutical Platinum-based Antineoplastic Product Offered
Table 128. Simcere Pharmaceutical Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 129. Simcere Pharmaceutical Main Business
Table 130. Simcere Pharmaceutical Latest Developments
Table 131. Abbvie Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 132. Abbvie Platinum-based Antineoplastic Product Offered
Table 133. Abbvie Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 134. Abbvie Main Business
Table 135. Abbvie Latest Developments
Table 136. Novartis Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 137. Novartis Platinum-based Antineoplastic Product Offered
Table 138. Novartis Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 139. Novartis Main Business
Table 140. Novartis Latest Developments
Table 141. GSK Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 142. GSK Platinum-based Antineoplastic Product Offered
Table 143. GSK Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 144. GSK Main Business
Table 145. GSK Latest Developments
Table 146. MSD Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 147. MSD Platinum-based Antineoplastic Product Offered
Table 148. MSD Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 149. MSD Main Business
Table 150. MSD Latest Developments
Table 151. Hengrui Medicine Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 152. Hengrui Medicine Platinum-based Antineoplastic Product Offered
Table 153. Hengrui Medicine Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 154. Hengrui Medicine Main Business
Table 155. Hengrui Medicine Latest Developments
Table 156. Hansoh Pharmaceutical Group Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 157. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Offered
Table 158. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 159. Hansoh Pharmaceutical Group Main Business
Table 160. Hansoh Pharmaceutical Group Latest Developments
Table 161. ChiTaiTianQing Pharmaceutical Group Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 162. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Offered
Table 163. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 164. ChiTaiTianQing Pharmaceutical Group Main Business
Table 165. ChiTaiTianQing Pharmaceutical Group Latest Developments
Table 166. CSPC Pharmaceutical Group Basic Information, Platinum-based Antineoplastic Manufacturing Base, Sales Area and Its Competitors
Table 167. CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Offered
Table 168. CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 169. CSPC Pharmaceutical Group Main Business
Table 170. CSPC Pharmaceutical Group Latest Developments
LIST OF FIGURES
Figure 1. Picture of Platinum-based Antineoplastic
Figure 2. Platinum-based Antineoplastic Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Platinum-based Antineoplastic Sales Growth Rate 2017-2028 (Units)
Figure 7. Global Platinum-based Antineoplastic Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Platinum-based Antineoplastic Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Cisplatin
Figure 10. Product Picture of Carboplatin
Figure 11. Product Picture of Nedaplatin
Figure 12. Product Picture of Oxaliplatin
Figure 13. Product Picture of Lobaplatin
Figure 14. Product Picture of Cycloplatin
Figure 15. Global Platinum-based Antineoplastic Sales Market Share by Type in 2021
Figure 16. Global Platinum-based Antineoplastic Revenue Market Share by Type (2017-2022)
Figure 17. Platinum-based Antineoplastic Consumed in Combination Therapy
Figure 18. Global Platinum-based Antineoplastic Market: Combination Therapy (2017-2022) & (Units)
Figure 19. Platinum-based Antineoplastic Consumed in Monotherapy
Figure 20. Global Platinum-based Antineoplastic Market: Monotherapy (2017-2022) & (Units)
Figure 21. Platinum-based Antineoplastic Consumed in Targeted Therapy
Figure 22. Global Platinum-based Antineoplastic Market: Targeted Therapy (2017-2022) & (Units)
Figure 23. Global Platinum-based Antineoplastic Sales Market Share by Application (2017-2022)
Figure 24. Global Platinum-based Antineoplastic Revenue Market Share by Application in 2021
Figure 25. Platinum-based Antineoplastic Revenue Market by Company in 2021 ($ Million)
Figure 26. Global Platinum-based Antineoplastic Revenue Market Share by Company in 2021
Figure 27. Global Platinum-based Antineoplastic Sales Market Share by Geographic Region (2017-2022)
Figure 28. Global Platinum-based Antineoplastic Revenue Market Share by Geographic Region in 2021
Figure 29. Global Platinum-based Antineoplastic Sales Market Share by Region (2017-2022)
Figure 30. Global Platinum-based Antineoplastic Revenue Market Share by Country/Region in 2021
Figure 31. Americas Platinum-based Antineoplastic Sales 2017-2022 (Units)
Figure 32. Americas Platinum-based Antineoplastic Revenue 2017-2022 ($ Millions)
Figure 33. APAC Platinum-based Antineoplastic Sales 2017-2022 (Units)
Figure 34. APAC Platinum-based Antineoplastic Revenue 2017-2022 ($ Millions)
Figure 35. Europe Platinum-based Antineoplastic Sales 2017-2022 (Units)
Figure 36. Europe Platinum-based Antineoplastic Revenue 2017-2022 ($ Millions)
Figure 37. Middle East & Africa Platinum-based Antineoplastic Sales 2017-2022 (Units)
Figure 38. Middle East & Africa Platinum-based Antineoplastic Revenue 2017-2022 ($ Millions)
Figure 39. Americas Platinum-based Antineoplastic Sales Market Share by Country in 2021
Figure 40. Americas Platinum-based Antineoplastic Revenue Market Share by Country in 2021
Figure 41. United States Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 42. Canada Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 43. Mexico Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 44. Brazil Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 45. APAC Platinum-based Antineoplastic Sales Market Share by Region in 2021
Figure 46. APAC Platinum-based Antineoplastic Revenue Market Share by Regions in 2021
Figure 47. China Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 48. Japan Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 49. South Korea Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 50. Southeast Asia Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 51. India Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 52. Australia Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 53. Europe Platinum-based Antineoplastic Sales Market Share by Country in 2021
Figure 54. Europe Platinum-based Antineoplastic Revenue Market Share by Country in 2021
Figure 55. Germany Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 56. France Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 57. UK Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 58. Italy Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 59. Russia Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 60. Middle East & Africa Platinum-based Antineoplastic Sales Market Share by Country in 2021
Figure 61. Middle East & Africa Platinum-based Antineoplastic Revenue Market Share by Country in 2021
Figure 62. Egypt Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 63. South Africa Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 64. Israel Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 65. Turkey Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 66. GCC Country Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 67. Manufacturing Cost Structure Analysis of Platinum-based Antineoplastic in 2021
Figure 68. Manufacturing Process Analysis of Platinum-based Antineoplastic
Figure 69. Industry Chain Structure of Platinum-based Antineoplastic
Figure 70. Channels of Distribution
Figure 71. Distributors Profiles
Figure 1. Picture of Platinum-based Antineoplastic
Figure 2. Platinum-based Antineoplastic Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Platinum-based Antineoplastic Sales Growth Rate 2017-2028 (Units)
Figure 7. Global Platinum-based Antineoplastic Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Platinum-based Antineoplastic Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Cisplatin
Figure 10. Product Picture of Carboplatin
Figure 11. Product Picture of Nedaplatin
Figure 12. Product Picture of Oxaliplatin
Figure 13. Product Picture of Lobaplatin
Figure 14. Product Picture of Cycloplatin
Figure 15. Global Platinum-based Antineoplastic Sales Market Share by Type in 2021
Figure 16. Global Platinum-based Antineoplastic Revenue Market Share by Type (2017-2022)
Figure 17. Platinum-based Antineoplastic Consumed in Combination Therapy
Figure 18. Global Platinum-based Antineoplastic Market: Combination Therapy (2017-2022) & (Units)
Figure 19. Platinum-based Antineoplastic Consumed in Monotherapy
Figure 20. Global Platinum-based Antineoplastic Market: Monotherapy (2017-2022) & (Units)
Figure 21. Platinum-based Antineoplastic Consumed in Targeted Therapy
Figure 22. Global Platinum-based Antineoplastic Market: Targeted Therapy (2017-2022) & (Units)
Figure 23. Global Platinum-based Antineoplastic Sales Market Share by Application (2017-2022)
Figure 24. Global Platinum-based Antineoplastic Revenue Market Share by Application in 2021
Figure 25. Platinum-based Antineoplastic Revenue Market by Company in 2021 ($ Million)
Figure 26. Global Platinum-based Antineoplastic Revenue Market Share by Company in 2021
Figure 27. Global Platinum-based Antineoplastic Sales Market Share by Geographic Region (2017-2022)
Figure 28. Global Platinum-based Antineoplastic Revenue Market Share by Geographic Region in 2021
Figure 29. Global Platinum-based Antineoplastic Sales Market Share by Region (2017-2022)
Figure 30. Global Platinum-based Antineoplastic Revenue Market Share by Country/Region in 2021
Figure 31. Americas Platinum-based Antineoplastic Sales 2017-2022 (Units)
Figure 32. Americas Platinum-based Antineoplastic Revenue 2017-2022 ($ Millions)
Figure 33. APAC Platinum-based Antineoplastic Sales 2017-2022 (Units)
Figure 34. APAC Platinum-based Antineoplastic Revenue 2017-2022 ($ Millions)
Figure 35. Europe Platinum-based Antineoplastic Sales 2017-2022 (Units)
Figure 36. Europe Platinum-based Antineoplastic Revenue 2017-2022 ($ Millions)
Figure 37. Middle East & Africa Platinum-based Antineoplastic Sales 2017-2022 (Units)
Figure 38. Middle East & Africa Platinum-based Antineoplastic Revenue 2017-2022 ($ Millions)
Figure 39. Americas Platinum-based Antineoplastic Sales Market Share by Country in 2021
Figure 40. Americas Platinum-based Antineoplastic Revenue Market Share by Country in 2021
Figure 41. United States Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 42. Canada Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 43. Mexico Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 44. Brazil Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 45. APAC Platinum-based Antineoplastic Sales Market Share by Region in 2021
Figure 46. APAC Platinum-based Antineoplastic Revenue Market Share by Regions in 2021
Figure 47. China Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 48. Japan Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 49. South Korea Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 50. Southeast Asia Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 51. India Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 52. Australia Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 53. Europe Platinum-based Antineoplastic Sales Market Share by Country in 2021
Figure 54. Europe Platinum-based Antineoplastic Revenue Market Share by Country in 2021
Figure 55. Germany Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 56. France Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 57. UK Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 58. Italy Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 59. Russia Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 60. Middle East & Africa Platinum-based Antineoplastic Sales Market Share by Country in 2021
Figure 61. Middle East & Africa Platinum-based Antineoplastic Revenue Market Share by Country in 2021
Figure 62. Egypt Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 63. South Africa Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 64. Israel Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 65. Turkey Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 66. GCC Country Platinum-based Antineoplastic Revenue Growth 2017-2022 ($ Millions)
Figure 67. Manufacturing Cost Structure Analysis of Platinum-based Antineoplastic in 2021
Figure 68. Manufacturing Process Analysis of Platinum-based Antineoplastic
Figure 69. Industry Chain Structure of Platinum-based Antineoplastic
Figure 70. Channels of Distribution
Figure 71. Distributors Profiles
